The Institute of Robotic Surgery has purchased Surfacide UV-C emitting tower systems that will be used to kill superbugs, or multi-drug resistant organisms, including C.diff, MRSA, VRE, CRE and Acinetobacter in all its operating suites, labor, and delivery suites and isolation rooms.
The Surfacide System
The Surfacide Helios system implements multiple emitters through three towers that disinfect all exposed surfaces of the healthcare environments in a single 20 to 30-minute cycle, offering an effective additional line of defense for the Hospital’s maintenance staff.
“The Surfacide machine increases the efficacy of our accredited maintenance program in place to create a safe and clean environment for all our patients and visitors,” said Dr. Nizar Kifaieh, MD MBA, CPE, FACEP, President and CEO of The Institute of Robotic Surgery. “By allowing us to ‘see’ and reach areas that need to be disinfected in less time, our staff can work more efficiently, and increase the number of patients our doctors can accommodate.”
The Surfacide Helios system is one element of The Institute of Robotic Surgery.’s extensive patient safety and quality of care program which is accredited by the international standard DNV-GL, the first and only accreditation program to integrate National Integrated Accreditation for Healthcare Organizations (NIAHO®), the CMS Conditions of Participation with the ISO 9001 Quality Management Program (QMS).
Surfacide can detect anyone entering the room and shut off the three emitters instantly, ensuring patient, visitor and employee safety.